YOLFTbeta
Trevi Therapeutics Inc

Trevi Therapeutics Inc

TRVI · NASDAQ · Healthcare / Biotechnology

13.65USD+0.03 (+0.22%)

Price History

Full chart

Market Stats

Previous Close13.62
Open13.57
Day Range13.17 – 14.17
52-Week Range8.99 – 20.22
Volume1.10M
Market Cap2.05B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.35
Dividend Yield0.00%
Beta1.05
50-Day Avg17.11
200-Day Avg14.24

About

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Jennifer L. Good
  • Employees34
  • Headquarters195 Church Street, New Haven, CT, United States, 06510, USA
  • Websitehttps://www.trevitherapeutics.com

Leadership

  • Ms. Jennifer L. GoodCo-Founder, CEO, President, & Director · b. 1965
  • Dr. James V. Cassella Ph.D.Chief Development Officer · b. 1955
  • Dr. Thomas R. Sciascia M.D.Co-Founder & Chief Scientific Officer · b. 1953
  • Mr. David C. Hastings CPAChief Financial Officer & Principal Financial Officer · b. 1961
  • Mr. Christopher GallettaController & Chief Accounting Officer · b. 1978
  • Katie McManusCommunications Manager

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000000
Cost of Revenue4.00K023.00K39.00K47.00K50.00K43.00K123.00K147.00K132.00K
Gross Profit-4.00K0-23.00K-39.00K-47.00K-50.00K-43.00K-123.00K-147.00K-132.00K
Operating Expense8.62M8.24M18.39M26.61M32.44M32.43M29.86M33.80M51.38M49.20M
Operating Income-8.63M-8.24M-18.41M-26.64M-32.49M-32.48M-29.91M-33.92M-51.52M-49.33M
EBITDA-8.62M-8.19M-18.39M-26.61M-32.44M-32.71M-29.86M-28.58M-47.79M-42.68M
Net Income-11.09M-12.86M-20.55M-26.05M-32.76M-33.94M-29.15M-29.07M-47.91M-42.76M
R&D6.91M6.09M14.07M19.34M22.33M22.98M19.83M23.68M39.38M33.48M
Interest Expense03.34M174.00K616.00K456.00K1.20M780.00K391.00K4.00K0

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets8.41M22.23M20.49M60.00M47.13M38.48M123.02M89.40M110.90M193.44M
Total Liabilities25.82M7.45M3.18M5.46M19.85M21.40M15.56M6.86M11.26M10.20M
Total Equity-17.41M14.78M17.31M54.55M27.28M17.07M107.46M82.55M99.64M183.24M
Cash8.29M22.02M17.16M57.31M45.00M36.83M12.59M32.40M34.10M18.91M
Total Debt22.11M5.29M1.10M356.00K14.26M14.63M9.18M1.34M1.03M753.00K
Net Debt13.82M-16.73M-16.07M-56.96M-30.79M-22.20M-3.41M-31.06M-33.06M-18.16M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.19M-7.97M-18.29M-23.09M-29.00M-28.95M-28.18M-31.71M-38.26M-42.09M
Investing Cash Flow-13.00K-13.00K-158.00K-9.00K-32.00K-107.37M-107.37M59.43M-21.53M-94.11M
Financing Cash Flow8.60M21.72M3.63K73.21M16.72M20.77M111.31M-7.91M61.48M121.01M
Capital Expenditure13.00K13.00K158.00K9.00K32.00K159.00K159.00K137.00K35.00K12.00K
Free Cash Flow-11.19M-7.99M-18.45M-23.10M-29.03M-28.95M-28.33M-31.85M-38.29M-42.10M
Dividends Paid0002.24M------
FCF to OCF100.00%100.16%100.86%100.04%100.11%100.00%100.56%100.43%100.09%100.03%
Dividend Paid to FCF0.00%0.00%0.00%-9.69%------

Earnings

Report DateDec 21, 2018Feb 27, 2019Jun 13, 2019Aug 12, 2019Nov 14, 2019Mar 16, 2020May 7, 2020Aug 13, 2020Nov 12, 2020Mar 25, 2021May 13, 2021Aug 12, 2021Nov 10, 2021Mar 17, 2022May 12, 2022Aug 11, 2022Nov 10, 2022Mar 16, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 20, 2024May 7, 2024Aug 8, 2024Nov 6, 2024Mar 18, 2025May 8, 2025Aug 7, 2025Nov 13, 2025Mar 25, 2026May 5, 2026Aug 6, 2026Nov 12, 2026
EPS Estimate0.000.00-0.52-0.41-0.47-0.51-0.44-0.48-0.51-0.44-0.52-0.46-0.39-0.30-0.29-0.18-0.13-0.10-0.07-0.09-0.09-0.09-0.09-0.11-0.11-0.12-0.12-0.10-0.10-0.10-0.07-0.11-0.13
EPS Actual-0.590.00-13.85-0.41-0.41-0.37-0.48-0.41-0.41-0.51-0.43-0.49-0.34-0.28-0.24-0.14-0.12-0.06-0.06-0.07-0.08-0.08-0.11-0.12-0.13-0.11-0.09-0.09-0.08-0.06-0.09-0.11-
Surprise---2563.46%0.00%12.77%27.45%-9.09%14.58%19.61%-15.91%17.31%-6.52%12.82%6.67%17.24%22.22%7.69%40.00%14.29%22.22%11.11%11.11%-22.22%-9.09%-18.18%6.06%25.00%10.00%20.00%39.09%-28.57%0.00%-
Timing--After-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap2.05B
Enterprise Value1.74B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book6.41
EPS-0.35
Book Value2.26
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-59.42M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-19.66%
Return on Assets-13.82%
Shares Outstanding142.48M
Shares Float118.32M
Beta1.05
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 28.18
  • Strong Buy
    7
  • Buy
    1

Ownership Breakdown

Institutions
107.64%
Insiders
0.63%
Retail / Other
0.00%

Top Institutional Holders

  • NEA Management Company, LLC
    13.22M9.28%
  • BlackRock Inc
    10.24M7.19%
  • Frazier Life Sciences Management, L.P.
    9.94M6.98%
  • FMR Inc
    8.04M5.64%
  • Wellington Management Company LLP
    5.68M3.99%
  • Vivo Capital, LLC
    5.09M3.58%
  • Vanguard Capital Management, LLC
    4.98M3.49%
  • Marshall Wace Asset Management Ltd
    3.97M2.78%
  • Rubric Capital Management LP
    3.71M2.61%
  • Viking Global Investors LP
    3.20M2.25%
  • MPM Oncology Impact Management LP
    3.07M2.16%
  • Frontier Capital Management CO Inc
    3.07M2.16%
  • AllianceBernstein L.P.
    2.85M2.00%
  • Geode Capital Management, LLC
    2.78M1.95%
  • State Street Corp
    2.67M1.87%
  • Eventide Asset Management, LLC
    2.66M1.87%
  • Orbimed Advisors LLC
    2.45M1.72%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    4.06M2.85%
  • iShares Russell 2000 ETF
    2.72M1.91%
  • Eventide Healthcare & Life Sciences I
    2.66M1.87%